BD Receives FDA 510(k) Clearance For Updated BD Alaris Infusion System
Portfolio Pulse from Happy Mohamed
BD (Becton, Dickinson and Company) (NYSE:BDX) has received FDA 510(k) clearance for its updated BD Alaris™ Infusion System, enabling both remediation and a return to full commercial operations. The system is the only modular and comprehensive infusion system on the U.S. market. BD does not expect any material incremental revenue contribution from the BD Alaris™ Infusion System for the remainder of FY23, but expects to absorb initial re-launch investments within FY23 guidance range.
July 21, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BD has received FDA clearance for its updated BD Alaris™ Infusion System. However, the company does not expect any material incremental revenue contribution from the system for the remainder of FY23.
The FDA clearance is a positive development for BD, as it allows the company to return to full commercial operations for its infusion system. However, the company does not expect this to contribute significantly to its revenue for the remainder of FY23, which could limit the short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100